Matches in Nanopublications for { ?s ?p "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion description "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.
- NP1249176.RAxT2xUtmsvOZjVlrN0Wz3SXKAZL1rEPkI4xs_8iQHWJo130_assertion description "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249176.RAxT2xUtmsvOZjVlrN0Wz3SXKAZL1rEPkI4xs_8iQHWJo130_provenance.